Tanajak et al. proved that long-term administration of FGF21 to rats with insulin resistance and obesity markedly improved tissue insulin sensitivity and myocardial function through the activation of antiapoptotic and mitochondrial signaling pathways [101]. This evidence concerns the gene FGF21 and obesity disorder.